Mayoly brings colchicine production back to France, securing domestic supply of an essential gout medication
Executive summary: Mayoly opened a colchicine manufacturing facility in Auxerre, France, on June 23, 2026. Domestic production ensures a stable supply of an essential gout medication for over 600,000 French patients and lessens dependence on imports. Mayoly (French pharmaceutical lab), French healthcare system, patients requiring colchicine, and relevant regulatory authorities. The plant will ramp up output; stakeholders will monitor production volumes, pricing, and whether other firms follow similar reshoring initiatives.
The French laboratory Mayoly has inaugurated a new production line in Auxerre to manufacture colchicine, a drug prescribed to more than 600,000 patients in France and listed as a medicine of major therapeutic interest. This move reduces the country's reliance on foreign suppliers for a critical medication and aligns with broader efforts to strengthen pharmaceutical sovereignty. The inauguration highlights how reshoring can address supply‑chain vulnerabilities while supporting local manufacturing capacity.
Connected developments
- France curbs public drinking as heatwave hits music festival crowds
- Les canicules plombent la croissance, déplore le gouverneur de la Banque de France
- Canicule : en Ile-de-France, les usagers se détournent des transports en commun, métro, bus et RER étant peu, voire pas, climatisés
- France’s far-right leader Jordan Bardella tours Poland in search for new allies
Open the full case file on Beyond →
Social Pulse
AI estimate · not scraped